Balancing standardization and personalization will require establishing international standards for multi‐modal radiomics and patient‐derived organoid biobanks, with organoid drug sensitivity testing already improving objective response rates in IDH‐mutant glioma patients. Here, IDH1 is linked to central nervous system cancer.